When should I use CBNAAT (Cartridge-Based Nucleic Acid Amplification Test, GeneXpert) versus TrueNat for detecting Mycobacterium tuberculosis and rifampicin resistance?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 29, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

CBNAAT vs TrueNat: When to Use Each Test

Use CBNAAT (Xpert MTB/RIF or Xpert Ultra) as the primary molecular test for TB diagnosis in most clinical settings, particularly when rifampicin resistance detection is critical and infrastructure permits; reserve TrueNat for peripheral/point-of-care settings where portability and lower complexity are essential, recognizing its lower sensitivity compared to Xpert Ultra.

Key Performance Differences

CBNAAT (Xpert Ultra) Performance

  • Pulmonary TB detection: Sensitivity 93.7% (90.4-95.9%), Specificity 95.3% (90.9-97.7%) 1
  • Rifampicin resistance: Sensitivity >92%, Specificity >99% 2
  • Smear-positive cases: 96% sensitivity, 85% specificity 2
  • Smear-negative cases: 66% sensitivity, 98% specificity 2

TrueNat Performance

  • TrueNat MTB: Sensitivity 81.0% (72.8-87.2%), Specificity 97.0% (91.9-98.9%) 1
  • TrueNat MTB Plus: Sensitivity 90.6% (83.7-94.8%), Specificity 95.7% (94.7-96.5%) 1
  • Rifampicin resistance (MTB-RIF Dx): Sensitivity ranges 53-85%, Specificity 97% 1

Critical finding: Direct comparative studies demonstrate Xpert Ultra has significantly higher sensitivity than TrueNat MTB (93.7% vs 81.0%), though TrueNat has marginally higher specificity 1.

Clinical Decision Algorithm

Use CBNAAT (Xpert Ultra) When:

  1. High clinical suspicion for TB - The superior sensitivity of Xpert Ultra (93.7%) makes it preferable when missing a diagnosis would significantly impact mortality 1

  2. Rifampicin resistance detection is priority - Xpert has >92% sensitivity for rifampicin resistance with >99% specificity 2, compared to TrueNat's 53-85% sensitivity 1

  3. Patients at risk for drug resistance:

    • Previous TB treatment
    • Born/lived ≥1 year in countries with TB incidence ≥20/100,000 or MDR-TB prevalence ≥2%
    • Contacts of MDR-TB patients
    • HIV-infected patients 2

  4. Central/intermediate laboratory settings - Where infrastructure and power supply are reliable

  5. Extrapulmonary TB - Particularly for:

    • Tuberculous meningitis: Xpert Ultra shows 88.2% sensitivity, 96.0% specificity 3
    • Lymph node aspirates: 71.3% sensitivity, 97.4% specificity 3

Use TrueNat When:

  1. Peripheral/point-of-care settings - Battery-operated, portable, chip-based technology enables decentralized testing 4

  2. Resource-limited settings - Lower complexity and infrastructure requirements 4

  3. TrueNat MTB Plus specifically (not original MTB):

    • Performs better than original TrueNat MTB with ~30 CFU/ml limit of detection 4
    • Sensitivity 90.6% approaches Xpert Ultra 1
    • Avoid original TrueNat MTB due to high false-positive rate (specificity only 86.1%) 1

  4. When Xpert Ultra unavailable - As acceptable alternative for TB detection, but not for rifampicin resistance screening

Critical Caveats

False-Positive Concerns

TrueNat MTB has concerning false-positive rate (specificity 86.1%) compared to TrueNat MTB Plus (95.7%) or Xpert Ultra (95.3%) 1. This is particularly problematic in low-prevalence settings where positive predictive value drops significantly.

Rifampicin Resistance Detection Limitations

TrueNat MTB-RIF Dx has inadequate sensitivity (53-85%) for rifampicin resistance 1. Do not rely on TrueNat for excluding rifampicin resistance in high-risk patients. If TrueNat shows rifampicin resistance, confirm with culture-based DST or line probe assay.

Smear-Negative Cases

Both tests have reduced sensitivity in smear-negative cases. A negative NAAT result cannot exclude TB when clinical suspicion is moderate-to-high 2, 5. Always:

  • Proceed with mycobacterial culture (both liquid and solid media) 2
  • Consider repeat testing on additional specimens
  • Use clinical judgment for treatment initiation

Inhibitor Detection

If AFB smear is positive but NAAT is negative, test for PCR inhibitors (present in 3-7% of specimens) 5. If inhibitors detected, collect new specimen for repeat testing.

Practical Implementation

Specimen Requirements

  • Both tests: Results should be available within 48 hours of collection 5
  • Reserve sufficient specimen for culture - Culture remains gold standard for drug susceptibility testing and genotyping 5
  • Multiple specimens: Consider testing 2-3 specimens when initial result is negative but suspicion remains high

Interpretation Framework

If NAAT positive + AFB smear positive: Presume TB, initiate treatment (PPV >95%) 5

If NAAT positive + AFB smear negative: Use clinical judgment; consider confirming with second specimen, particularly with TrueNat MTB (not Plus) due to false-positive concerns 5

If NAAT negative + AFB smear positive: Test for inhibitors, repeat NAAT on new specimen; if persistently negative without inhibitors, consider nontuberculous mycobacteria 5

If NAAT negative + AFB smear negative: Cannot exclude TB; proceed with culture and additional diagnostic workup based on clinical suspicion 5

Evidence Gaps

  • Limited pediatric data for both platforms, particularly TrueNat 4
  • TrueNat MTB Ultima requires larger validation studies 4
  • Extrapulmonary TB: More robust evidence needed for TrueNat performance in non-pulmonary specimens 3

References

Related Questions

What are the recommended guidelines for using the Cartridge‑Based Nucleic Acid Amplification Test (CBNAAT) to diagnose tuberculosis and assess rifampicin resistance?
Can Gene Xpert (Xpert MTB/RIF) be performed on peritoneal fluid?
What anti‑tuberculosis regimen should be initiated for a 48‑kg patient with a creatinine clearance of approximately 63 mL/min and rifampicin‑resistant Mycobacterium tuberculosis?
Is the Xpert MTB/RIF assay appropriate for diagnosing tuberculosis in pleural fluid, cerebrospinal fluid (CSF), and ascitic fluid?
Which antibiotics, especially rifampin, are contraindicated with live attenuated vaccines and what timing adjustments are recommended?
What key history questions should be asked for a tick bite and under what circumstances are laboratory investigations indicated?
What is the appropriate treatment for an internal thrombosed hemorrhoid?
How should perianal swelling be evaluated and managed?
What ICD‑10 code should be used for an unspecified acute viral infection?
What are the differences and clinical purposes of transabdominal ultrasound, transvaginal ultrasound, and a complete pelvic ultrasound?
What is the recommended management for hepatic steatosis with insulin resistance in a patient without diabetes?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.